Interventional Open-Label Positron Emission Tomography Study Investigating Blood-Brain-Barrier Penetration and Pharmacokinetic Properties of [11C]-Lu AF90103 in Healthy Young Men
Latest Information Update: 18 Jul 2022
At a glance
- Drugs Lu AF90103 (Primary)
- Indications Unspecified
- Focus Pharmacokinetics
- Sponsors Lundbeck A/S
Most Recent Events
- 12 Jul 2022 Status changed from recruiting to completed.
- 06 May 2022 Planned primary completion date changed from 2 Jun 2022 to 31 May 2022.
- 07 Apr 2022 New trial record